← Leaderboards
Timothy Vollmer
Yale University
$103,605
Attributed
$103,605
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$103,605 · 3
By mechanism
M01$103,605 · 3
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- William V Tamborlane$15,237,030
- Elinore F. McCance-Katz$13,032,111
- Stephanie S O'Malley$41,813,757
- Edward Chu$17,954,928
- Thomas Richard Kosten$19,160,340
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationHuman SubjectNervous System Disorder ChemotherapyClinical ResearchMultiple SclerosisHuman Therapy EvaluationAminopyridinesDisease /Disorder Prevention /ControlImmunopathology ChemotherapyImmunotherapyInterferon BetaMagnetic Resonance ImagingOutcomes ResearchPathologic ProcessDrug Adverse EffectClinical TrialsOral AdministrationPharmacokineticsPlacebosDosage
Grant awards (4)
PHASE III SAFETY AND EFFICACY EVALUATION OF BETASERON IN MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
PHASE III SAFETY AND EFFICACY EVALUATION OF BETASERON IN MULTIPLE SCLEROSIS$34,535
M01 · FY2000 · RR
OPEN LABEL PROTOCOL TO ASSESS STEADY STATE PHARMACOKINETICS OF FAMPRIDINE$34,535
M01 · FY2000 · RR
OPEN LABEL DOSE PROPORTIONALITY--ASSESS SAFETY/TOLERABILITY OF FAMPRIDINE (4AP)$34,535
M01 · FY2000 · RR